Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 5 | 2018 | 114 | 0.630 |
Why?
|
| Hepatitis C, Chronic | 4 | 2018 | 32 | 0.570 |
Why?
|
| Liver Cirrhosis | 6 | 2024 | 74 | 0.560 |
Why?
|
| Esophageal Diseases | 1 | 2017 | 13 | 0.530 |
Why?
|
| Hematoma | 1 | 2017 | 26 | 0.530 |
Why?
|
| Ribavirin | 4 | 2013 | 9 | 0.500 |
Why?
|
| Liver Neoplasms | 6 | 2024 | 167 | 0.480 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2024 | 285 | 0.420 |
Why?
|
| Interferon-alpha | 3 | 2013 | 50 | 0.400 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 101 | 0.370 |
Why?
|
| Pain Clinics | 1 | 2010 | 2 | 0.330 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 54 | 0.320 |
Why?
|
| Cross Infection | 1 | 2010 | 37 | 0.320 |
Why?
|
| Hepatitis C | 4 | 2013 | 41 | 0.300 |
Why?
|
| Prednisone | 1 | 2008 | 53 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 133 | 0.290 |
Why?
|
| Hearing Loss | 1 | 2008 | 39 | 0.290 |
Why?
|
| Glucocorticoids | 1 | 2008 | 115 | 0.280 |
Why?
|
| Lamivudine | 1 | 2007 | 2 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hepatitis B | 1 | 2007 | 13 | 0.270 |
Why?
|
| MicroRNAs | 2 | 2024 | 301 | 0.250 |
Why?
|
| Middle Aged | 11 | 2024 | 7310 | 0.180 |
Why?
|
| Male | 12 | 2024 | 13771 | 0.180 |
Why?
|
| Gastroenterology | 1 | 2001 | 15 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 29 | 0.180 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2013 | 22 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 41 | 0.170 |
Why?
|
| Humans | 17 | 2024 | 28581 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 2045 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2001 | 116 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 66 | 0.160 |
Why?
|
| Indoles | 2 | 2013 | 110 | 0.160 |
Why?
|
| Inflammation | 1 | 2024 | 641 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2020 | 80 | 0.160 |
Why?
|
| Hepacivirus | 3 | 2018 | 48 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 409 | 0.140 |
Why?
|
| Aged | 7 | 2024 | 5525 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 13 | 0.130 |
Why?
|
| Rectal Diseases | 1 | 2017 | 10 | 0.130 |
Why?
|
| Choristoma | 1 | 2017 | 7 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 35 | 0.130 |
Why?
|
| Endoscopy | 1 | 2017 | 57 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 100 | 0.120 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Biopsy | 2 | 2010 | 207 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2018 | 2402 | 0.120 |
Why?
|
| Time Factors | 3 | 2015 | 1600 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 134 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 124 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 478 | 0.110 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 415 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 146 | 0.100 |
Why?
|
| Adult | 7 | 2018 | 7922 | 0.100 |
Why?
|
| Viral Load | 2 | 2010 | 32 | 0.100 |
Why?
|
| Carcinogenesis | 2 | 2024 | 81 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2612 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2010 | 7 | 0.090 |
Why?
|
| Medical History Taking | 1 | 2010 | 20 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2010 | 15 | 0.080 |
Why?
|
| Female | 7 | 2024 | 15471 | 0.080 |
Why?
|
| Hepatitis C Antibodies | 1 | 2010 | 7 | 0.080 |
Why?
|
| Risk Factors | 3 | 2014 | 2111 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 145 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 70 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2010 | 68 | 0.080 |
Why?
|
| alpha-Fetoproteins | 2 | 2020 | 18 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2010 | 265 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 734 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2010 | 622 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 76 | 0.070 |
Why?
|
| Acute Disease | 1 | 2007 | 155 | 0.070 |
Why?
|
| Liver | 1 | 2010 | 456 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 141 | 0.060 |
Why?
|
| Oklahoma | 1 | 2010 | 1038 | 0.060 |
Why?
|
| Tumor Virus Infections | 1 | 2005 | 14 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 681 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 27 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 64 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1338 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2024 | 52 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2024 | 273 | 0.050 |
Why?
|
| Young Adult | 1 | 2010 | 2804 | 0.050 |
Why?
|
| Anesthesia Recovery Period | 1 | 2001 | 2 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2002 | 128 | 0.040 |
Why?
|
| Neoplasms | 1 | 2010 | 857 | 0.040 |
Why?
|
| Physician's Role | 1 | 2001 | 29 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 42 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 53 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 4 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 20 | 0.040 |
Why?
|
| Bilirubin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 27 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2018 | 35 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2017 | 9 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2017 | 59 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 461 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 475 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 49 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 378 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 137 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 110 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1601 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 319 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 332 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 247 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 274 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 770 | 0.030 |
Why?
|
| Hepatorenal Syndrome | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 1 | 2014 | 5 | 0.030 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 5 | 0.030 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 3 | 0.030 |
Why?
|
| Peritonitis | 1 | 2014 | 15 | 0.030 |
Why?
|
| Ascites | 1 | 2014 | 19 | 0.030 |
Why?
|
| Hyponatremia | 1 | 2014 | 17 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 10580 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2014 | 56 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 682 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 465 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 208 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 815 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 67 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 523 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 461 | 0.020 |
Why?
|
| Pharmacology, Clinical | 1 | 2010 | 4 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 51 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 36 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 4732 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 79 | 0.020 |
Why?
|
| Self Report | 1 | 2010 | 121 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2010 | 63 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 172 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 134 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1454 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2008 | 9 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 224 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 190 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 994 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 611 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 58 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 1272 | 0.010 |
Why?
|
| Telangiectasis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 78 | 0.010 |
Why?
|
| ROC Curve | 1 | 2002 | 144 | 0.010 |
Why?
|
| Platelet Count | 1 | 2002 | 111 | 0.010 |
Why?
|
| Logistic Models | 1 | 2002 | 409 | 0.010 |
Why?
|
| Sex Factors | 1 | 2002 | 467 | 0.010 |
Why?
|